<DOC>
	<DOCNO>NCT02559687</DOCNO>
	<brief_summary>In study participant advanced/metastatic adenocarcinoma squamous cell carcinoma esophagus advanced/metastatic Siewert type I adenocarcinoma gastroesophageal junction ( GEJ ) previously treat two standard therapy treat pembrolizumab</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Previously-Treated Participants With Advanced Carcinoma Esophagus Esophagogastric Junction ( MK-3475-180/KEYNOTE-180 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great 3 month Histologicallyproven advanced/metastatic adenocarcinoma squamous cell carcinoma esophagus advanced/metastatic Siewert type 1 adenocarcinoma EGJ Documented objective radiographic clinical disease progression two previous line standard therapy Measurable disease base Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 Can provide either newly obtain archival tumor tissue sample intratumoral immunerelated testing antiprogrammed cell death ( PD1 ) Female participant childbearing potential must willing use adequate contraception course study 120 day last dose study medication Male participant must agree use adequate contraception start first dose 120 day last dose study medication Adequate organ function Currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose study medication Has active autoimmune disease require systemic treatment within 2 year prior first dose study medication Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Known central nervous system ( CNS ) metastases and/or carcinomatous meningitis Prior anticancer mAb , chemotherapy , target small molecule therapy , radiation therapy within 2 week prior first dose study medication recover adverse event due previously administer agent Prior therapy PD1 , antiPDLigand 1 ( PDL1 ) , antiPDL2 agent , previously participate Merck pembrolizumab ( MK3475 ) study Has know additional malignancy progress require active treatment within last 5 year exception curatively treat basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy , insitu cervical cancer , insitu intramucosal pharyngeal cancer Received live vaccine within 30 day first dose study medication Known history Human Immunodeficiency Virus ( HIV ) infection Known active Hepatitis B C History noninfectious pneumonitis require steroid current pneumonitis Active infection require systemic therapy Known psychiatric substance abuse disorder would interfere cooperation requirement study Pregnant , breastfeeding , expect conceive father child within project duration study , start screen visit 120 day last dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL1</keyword>
</DOC>